Specialty Pharmacy

Positive results were based on the PROSPER trial, which evaluated the overall survival of enzalutamide plus androgen deprivation therapy versus standard of care.

Capmatinib is an investigational, oral, and selective MET inhibitor, and if approved, it will be the first therapy to specifically target METex14 mutated advanced lung cancer, according to the company.

While KTE-X19 is not yet approved in any country, its Marketing Authorization Application has been validated in the European Union, and its target action date in the United States is August 10, 2020.

Top news from across the health care landscape.

Two studies published in The Lancet have developed models to examine what may happen if the World Health Organization commits to a 3-part strategy to end cervical cancer.

Clinical trials are now evaluating the potential combination of PARP inhibitors with immunotherapy or other agents in patients with ovarian cancer.

Meaningful improvements in outcomes with immunotherapy in recent years are finally starting to change the tide for the first-line treatment of patients with small-cell lung cancer.

Merck has announced its plan to spin-off products from its women's health, trusted legacy brands, and biosimilars into a new, independent, and publicly traded corporation, according to the company.

Top news from across the health care landscape.

Although the prevalence of health system-based specialty pharmacies has grown steadily over the past decade, 2020 will mark a critical year.

Top news from across the health care landscape.

Top news of the week from Specialty Pharmacy Times.

With emerging research from The Sidney Kimmel Cancer Center-Jefferson Health, outcomes in patients with uveal melanoma that has metastasized were shown to significantly improve with changes in treatment.

In addition to safety and tolerability, a pair of clinical studies will evaluate the drug’s efficacy and ability to slow disease progression and to improve quality of life in patients with amyotrophic lateral sclerosis.

A study conducted by LSU Health found that by the time recommended screening for colorectal cancer begins, the disease has already spread in a high percentage of patients.

Top news from across the health care landscape.

Upadactinib met the primary endpoint for patients with active psoriatic arthritis who had responded inadequately or were intolerant to 1 or more non-biologic disease modifying anti-rheumatic drugs.

A new report from the Florida Pharmacy Association and American Pharmacy Cooperative, Inc, alleges that pharmacy benefit managers (PBMs) in the state are favoring their own affiliated pharmacies in the Florida Medicaid Program, both by driving customers to those pharmacies and by reimbursing them at higher rates.

As the industry focuses more on value-based care, predictive modeling allows pharmacies to shift their services from a one-size-fits-all approach to a personalized, high-touch strategy.

Top news of the day from across the health care landscape.

New technique addresses the tendency of most CAR-T therapies to provoke immune responses against healthy tissues in patients.

Several viable models continue to emerge for addressing the unique challenges of payment and financing for innovative, durable, curative gene and cell therapies.

Not only is cancer control a matter of public health, but its value should be viewed as an investment with considerable human and economic returns, according to a newly released report from the World Health Organization (WHO). Furthermore, although disparities between cancer care in lower- and higher-income countries may seem overwhelming, the report emphasized that they are entirely solvable with effective national cancer control plans.

Top news of the day from across the health care landscape.

The mechanism behind HIV resistance affects the ability of integrase strand transfer inhibitors to bind and block the HIV enzyme integrase.

Health systems, including inpatient and non-acute environments, will have a nearly 4% price increase for pharmaceutical purchases in the coming year, according to the report.

Top news of the day from across the health care landscape.

Canakinumab, a fully human monoclonal antibody, targets interleukin-1β, has anti-inflammatory effects, and is FDA-approved for rheumatologic disorders. Interleukein-1β is a cytokine that drives the interleukin(IL)-6 signaling pathway in inflammatory response.